Cachexia

(redirected from Cancer cachexia)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Cancer cachexia: paraneoplastic syndrome

cachexia

[ka′kek·sē·ə]
(medicine)
Weight loss, weakness, and wasting of the body encountered in certain diseases or in terminal illnesses.

Cachexia

 

a state of profound wasting and physical debility manifested by severe emaciation, weight loss, dry and flabby skin, loss of hair, disappearance of subcutaneous fat, atrophy of muscles and viscera, and low serum protein level. Edema, hemorrhages, and sometimes mental derangement can occur with cachexia. It results from prolonged malnutrition or starvation, severe metabolic disorders, chronic arsenic, lead, mercury, or fluorine poisoning, and severe lesions of the digestive tract (atrophy of the intestinal mucosa, condition after resection of the stomach and intestines). Cachexia may occur in severe cases of tuberculosis or other chronic infections, some lesions of the endocrine glands, (hypophysis, thyroid, adrenals, pancreas), large slow-healing wounds, abscesses, and malignant tumors (especially of the esophagus and stomach).

References in periodicals archive ?
In the present study, we evaluate the effect of parthenolide for the treatment of cancer cachexia in a cancer cachexia model by subcutaneously grafted CT26 tumor fragments into BALB/c mice.
A preclinical model of cancer cachexia found that MT-102 demonstrated superior efficacy relative to other tested agents.
L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase.
The use of bioelectrical impedance analysis to predict total body water in patients with cancer cachexia.
Effect of branched-chain amino acids on muscle atrophy in cancer cachexia.
WIGMORE, SJ; FEARON, KCH; MAINGAY, JP & ROSS, JA 1997: Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6.
Cancer cachexia impairs quality of life and response to therapy, increasing morbidity and mortality of cancer patients.
Cancer cachexia affects between 50% and 80% of cancer patients, according to Nagi B.
This report provides comprehensive information on the therapeutic d evelopment for Cancer Cachexia .
Ostarine is a small molecule, orally available, selective androgen receptor modulator (SARM) in phase III trials for use in cancer cachexia.
Cancer cachexia is a complex scenario resulting not only from a reduced nutrient intake, but also from the metabolic effects associated with the tumour and its associated treatment (surgery, chemotherapy, radiotherapy or hormonal treatment).
Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type.

Full browser ?